24558330|t|Interpatient variability in dexmedetomidine response: a survey of the literature.
24558330|a|Fifty-five thousand patients are cared for in the intensive care unit (ICU) daily with sedation utilized to reduce anxiety and agitation while optimizing comfort. The Society of Critical Care Medicine (SCCM) released updated guidelines for management of pain, agitation, and delirium in the ICU and recommended nonbenzodiazepines, such as dexmedetomidine and propofol, as first line sedation agents. Dexmedetomidine, an alpha-2 agonist, offers many benefits yet its use is mired by the inability to consistently achieve sedation goals. Three hypotheses including patient traits/characteristics, pharmacokinetics in critically ill patients, and clinically relevant genetic polymorphisms that could affect dexmedetomidine response are presented. Studies in patient traits have yielded conflicting results regarding the role of race yet suggest that dexmedetomidine may produce more consistent results in less critically ill patients and with home antidepressant use. Pharmacokinetics of critically ill patients are reported as similar to healthy individuals yet wide, unexplained interpatient variability in dexmedetomidine serum levels exist. Genetic polymorphisms in both metabolism and receptor response have been evaluated in few studies, and the results remain inconclusive. To fully understand the role of dexmedetomidine, it is vital to further evaluate what prompts such marked interpatient variability in critically ill patients. 
24558330	28	43	dexmedetomidine	Chemical	MESH:D020927
24558330	102	110	patients	Species	9606
24558330	197	204	anxiety	Disease	MESH:D001007
24558330	209	218	agitation	Disease	MESH:D011595
24558330	336	340	pain	Disease	MESH:D010146
24558330	342	351	agitation	Disease	MESH:D011595
24558330	357	365	delirium	Disease	MESH:D003693
24558330	393	411	nonbenzodiazepines	Chemical	-
24558330	421	436	dexmedetomidine	Chemical	MESH:D020927
24558330	441	449	propofol	Chemical	MESH:D015742
24558330	482	497	Dexmedetomidine	Chemical	MESH:D020927
24558330	502	509	alpha-2	Gene	170589
24558330	645	652	patient	Species	9606
24558330	697	711	critically ill	Disease	MESH:D016638
24558330	712	720	patients	Species	9606
24558330	786	801	dexmedetomidine	Chemical	MESH:D020927
24558330	837	844	patient	Species	9606
24558330	929	944	dexmedetomidine	Chemical	MESH:D020927
24558330	989	1003	critically ill	Disease	MESH:D016638
24558330	1004	1012	patients	Species	9606
24558330	1067	1081	critically ill	Disease	MESH:D016638
24558330	1082	1090	patients	Species	9606
24558330	1188	1203	dexmedetomidine	Chemical	MESH:D020927
24558330	1392	1407	dexmedetomidine	Chemical	MESH:D020927
24558330	1494	1508	critically ill	Disease	MESH:D016638
24558330	1509	1517	patients	Species	9606
24558330	Negative_Correlation	MESH:D020927	MESH:D003693
24558330	Negative_Correlation	MESH:D015742	MESH:D003693
24558330	Negative_Correlation	MESH:D015742	MESH:D011595
24558330	Negative_Correlation	MESH:D020927	MESH:D011595
24558330	Negative_Correlation	MESH:D020927	MESH:D010146
24558330	Negative_Correlation	MESH:D020927	MESH:D016638
24558330	Positive_Correlation	MESH:D020927	170589

